Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Combines biocompatibility, heat-resistance, transparency and durability
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Subscribe To Our Newsletter & Stay Updated